Thursday 16 October, 2025
Objectives: One of the well-known side effects of cisplatin, a chemotherapeutic agent used since the 1970s, is haematological toxicity[1]. However, little…
Read morePoster: Drug/Disease Modelling - Oncology
Immune Response Template for Quantitative Systems Pharmacology Modeling: Description of Co-inhibitory and Co-stimulatory Receptors Interaction
Thursday 16 October, 2025
Objectives: Immunotherapy is a new class of cancer treatment that works by activation of immune response of patient to fight…
Read moreExploring the use of constant and time-varying observation-based versus model-based tumour size metrics for early predictions of drug efficacy on overall survival in malignant pleural mesothelioma
Thursday 16 October, 2025
Objectives: Being able to characterise drug efficacy at an early stage during oncology clinical trials is of primary necessity for…
Read moreA semi-mechanistic model of targeted therapy for melanoma
Thursday 16 October, 2025
Introduction: Targeted therapy with BRAF inhibitors has resulted in significant progress in the treatment of metastatic melanoma bearing BRAF V600E…
Read moreTumour size measurements: impact of inter-operator variability on model-based drug effect evaluation
Thursday 16 October, 2025
Objectives: Being readily available during oncology clinical trials, tumour size (TS) measurements are commonly used as a biomarker for drug…
Read morePopulation pharmacodynamic characterization of automatically classified circulating tumor cells and vesicles and their relationship to survival in metastatic colorectal cancer patients
Thursday 16 October, 2025
Objectives: Liquid biopsies represent a promising advancement in cancer diagnostics, offering a minimally invasive approach to sampling that has potential…
Read moreSuccessful Establishment of Optimal Biological Dose (OBD) through PK/PD Modeling of BCL2/BIM Complex Disruption in Clinical Trials using a BCL-2 Inhibitor.
Thursday 16 October, 2025
Objectives: S65487 is an intravenous potent and selective inhibitor of B-cell leukemia/lymphoma-2 (BCL-2), member of the BCL-2 family proteins which…
Read moreA pharmacokinetic/pharmacodynamic model of cyclosporine A and its nephrotoxicity in patients after hematopoietic stem cell transplantation
Thursday 16 October, 2025
Objectives: Development of a pharmacokinetic/pharmacodynamic (PK/PD) model of Cyclosporine A (CyA) in patients after hematopoietic stem cell transplantation (HSCT) with…
Read morePopulation pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP)
Thursday 16 October, 2025
Objectives: Despite anticancer therapy, patients with locally advanced rectal cancer frequently suffer from relapses. A recent study in which sorafenib,…
Read moreOperating characteristics of TGI metrics to support early Phase Ib decisions in unresectable hepatocellular carcinoma patients based on an historical Phase III study (IMbrave150)
Thursday 16 October, 2025
Introduction: Recently, a modeling framework has been developed to assess the operating characteristics of tumor growth inhibition (TGI) metrics to…
Read more